Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Werewolf Therapeutics (HOWL) Return on Capital Employed (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Return on Capital Employed for 5 consecutive years, with 1.05% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed fell 55.0% to 1.05% in Q3 2025 year-over-year; TTM through Sep 2025 was 1.05%, a 55.0% decrease, with the full-year FY2024 number at 0.54%, down 27.0% from a year prior.
  • Return on Capital Employed was 1.05% for Q3 2025 at Werewolf Therapeutics, down from 0.86% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.24% in Q3 2023 to a low of 1.05% in Q3 2025.
  • A 5-year average of 0.46% and a median of 0.39% in 2022 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: grew 19bps in 2023, then plummeted -55bps in 2025.
  • Werewolf Therapeutics' Return on Capital Employed stood at 0.3% in 2021, then tumbled by -31bps to 0.39% in 2022, then soared by 34bps to 0.26% in 2023, then plummeted by -140bps to 0.62% in 2024, then plummeted by -68bps to 1.05% in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Return on Capital Employed are 1.05% (Q3 2025), 0.86% (Q2 2025), and 0.71% (Q1 2025).